🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very exciting to have our lab members, Despoina Karagianni Despoina Karagianni and Felipe Galvez-Cancino @galvez_cancino, be shortlisted in the Further, Faster, Together (Industry-Academia Collaboration) category in the #IEAwards2024 along with our amazing collaborators at Cancer Research Horizons

Proud to announce Team MATCHMAKERS has been one of the 5 successful Cancer Grand Challenges. Sergio Quezada UCL Cancer Institute is part of the Team that aims to decipher the T-cell receptor cancer-recognition code.

While in London, Gavin had the privilege of rounding our “Treats & Treasures Trolley” on the onc floor at Great Ormond Street Hospital for Children. Joining him were Sara Wakeling, co-founder of our UK partner org Alice's Arc & Helen Speight one of the fab nurses on the floor.

We can't wait to see you Dr. Delgoffe! Thanks for your leadership in bringing this awesome event to fruition! See everyone Sunday in sunny Miami!

Today is #InternationalWomensDay. We are proud to support the many women scientists, students and technical staff at the City of London Centre. Special thanks to our Executive and Theme Leads @MariamJHanjani AnitaGrigoriadis Frances Balkwill Hodivala-Dilke Lab Francesca Ciccarelli Karin Straathof💙🎗❤️

Absolutely honoured to be elected Fellow of the Academy of Medical Sciences together with amazing ⁦UCL⁩ colleagues!! Thanks to ⁦⁦UCL Cancer Institute⁩ ⁦Cancer Research UK⁩ and my amazing team ⁦Quezada Lab⁩ ucl.ac.uk/news/2024/may/…

Don´t miss this Review summarizing the different antibody-based approaches for targeting cancer cells including #CheckpointInhibitors, bispecific antibodies and #AntibodyDrugConjugates, as well as strategies that improve efficacy and reduce toxicities. go.nature.com/3wWetGE

Really happy to share a link to our most recent preprint: biorxiv.org/content/10.110…   In it we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the DECOD-Ag DECOD-Ag program.

Great collaboration with Marc Mansour yardena samuels Swanton Lab @SineRekerHAdrup UCL Cancer Institute and Achilles Therapeutics funded by Horizon 2020 News

Tremendous line up of speakers! Come join us in Boston!

Looking fwd to a great conference!!!

Enjoying the British summer with the tremendous team from ⁦Quezada Lab⁩.

Happy Post Doc Appreciation Week! Our facilities are used by Post Docs at UCL Cancer Institute, King's Faculty of Life Sciences & Medicine, Barts Cancer Institute (Queen Mary) and The Crick. We spoke to Alex Simpson in Quezada Lab at UCL Cancer Institute about life as a Post Doc. linkedin.com/feed/update/ur… #CelebratePostDocs

Many congratulations ⁦FabriceAndre⁩ ⁦Christina Curtis⁩ on the Susan G Komen awards - a great recognition for all your discoveries So well deserved

This is exactly right. Gutting the NIH will lead to a rapid labor shortage and all these jobs going overseas

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies: cell.com/immunity/fullt… Amazing collaboration led by Cancer Research UK funded Quezada Lab @galvez_cancino UCL Cancer Institute and colleagues!

CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises the risk of hematological malignancies, chronic inflammatory diseases (like heart & lung disease), & lung cancer. This manuscript shows that CHIP somatic

Depletion of Tregs with a non-IL-2-blocking anti-CD25  enhanced antitumor responses in brain tumors and synergized with anti-PD-1 or a tumor antigen-targeted antibody bit.ly/44nab9T  UCL Cancer Institute  Quezada Lab #Immunotherapy